

UNCLASSIFIED

Defense Technical Information Center  
Compilation Part Notice

ADP019725

TITLE: Biodistribution and Tumor-Targeting Potential of Poly[Ethylene Glycol]-Modified Gelatin Nanoparticles

DISTRIBUTION: Approved for public release, distribution unlimited

This paper is part of the following report:

TITLE: Materials Research Society Symposium Proceedings. Volume 845, 2005. Nanoscale Materials Science in Biology and Medicine, Held in Boston, MA on 28 November-2 December 2004

To order the complete compilation report, use: ADA434631

The component part is provided here to allow users access to individually authored sections of proceedings, annals, symposia, etc. However, the component should be considered within the context of the overall compilation report and not as a stand-alone technical report.

The following component part numbers comprise the compilation report:  
ADP019693 thru ADP019749

UNCLASSIFIED

## Biodistribution and Tumor-Targeting Potential of Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles

Goldie Kaul<sup>1</sup> and Mansoor Amiji<sup>2</sup>

Department of Pharmaceutical Sciences, School of Pharmacy,  
Northeastern University, Boston, MA 02115

### Abstract

In order to develop a safe and effective systemically-administered delivery system for solid tumors, the biodistribution of control gelatin and poly(ethylene-glycol) modified (PEGylated) gelatin nanoparticles was examined in Lewis lung carcinoma (LLC)-bearing female C57BL6 mice. Type B gelatin and PEGylated gelatin nanoparticles were radiolabeled ( $^{125}\text{I}$ ) for the *in vivo* biodistribution studies after intravenous (i.v.) administration through the tail vein in LLC-bearing mice. At various time intervals, the tumor-bearing mice were sacrificed and tumor, blood, and major organs were harvested for analysis of radioactivity corresponding to the localization of the nanoparticles. Percent recovered dose was determined and normalized to the weight of the tissue or fluid sample. Non-compartmental pharmacokinetic analysis was performed to determine the long-circulating property and preferential tumor targeting potential of PEGylated gelatin nanoparticles *in vivo*. From the radioactivity in plasma and various organs collected, it was evident that the majority of PEGylated nanoparticles were present either in the blood pool or taken up by the tumor mass and liver. For instance, after 3 hours, the PEGylated gelatin nanoparticles were almost 2-fold higher in the blood pool than the control gelatin nanoparticles. PEGylated gelatin nanoparticles remained in the blood pool for a longer period of time due to the steric repulsion effect of the PEG chains as compared to the control gelatin nanoparticles. In addition, approximately 4-5% of the recovered dose of PEGylated gelatin nanoparticles was present in the tumor mass for up to 12 hours. The plasma and the tumor half-lives, area-under-the-curve, and the mean residence time of the PEGylated gelatin nanoparticles were significantly greater than those of the control gelatin nanoparticles. The results of the study confirmed long-circulating property and preferential tumor targeting potential of PEGylated gelatin nanoparticles in a murine tumor model.

### Introduction

For efficient systemic delivery of drugs and genes in solid tumor therapy, they must be able to traverse through the circulatory system and reach the tumor mass in sufficient concentration, get transported across the microvessels, and diffuse into the interstitial space. Unfortunately, the irregular blood supply, high interstitial pressure, low pH and hypoxia, and lack of lymphatic system contribute to inefficient drug uptake and distribution in the tumor mass after systemic administration [1]. The problem of optimum delivery to tumors is further compounded by newer generation of pharmaceuticals, developed through advances in molecular biology and genetic engineering, which are hydrophilic macromolecules based on protein and nucleic acid chemistry, that inherently have very poor diffusional properties.

<sup>1</sup> Current address: Boston Scientific Corporation, 460 Pleasant Street, Watertown, MA

<sup>2</sup> Corresponding author: Tel. 617-373-3137, Fax. 617-373-8886, Email: m.amiji@neu.edu

Due to the hyperpermeability of the tumor vasculature and the lack of lymphatic drainage, blood-borne polymeric conjugate and nanoparticles are preferentially distributed in the tumor due to the *enhanced permeability and retention* (EPR) effect [2]. The enhanced vascular permeability of the tumor, developed through secretion of vascular permeability factors such as bradykinin, VEGF, and nitric oxide, allows for preferential uptake and increased residence time for polymeric drugs and colloidal systems in the vicinity of the tumor mass. Using poly(ethylene glycol) (PEG)-modified liposomes, Jain's group has shown that the effective vascular pore size of most peripheral human tumors range from 200 nm to 600 nm in diameter, with a mean of about 400 nm [3]. For delivery to solid tumor, surface modification of nanoparticles with water soluble polymers, such as PEG affords long circulation time and passive targeting potential to the tumor mass. In a review article Moghimi *et al.*, [4] have extensively discussed the development and applications of long-circulating and target-specific nanoparticles.

Previously, we have described the preparation and characterization of PEG-modified (PEGylated) gelatin nanoparticles as a hydrophilic, biocompatible, biodegradable matrix for delivery of hydrophilic molecules, such as plasmid DNA, to solid tumors [5]. Type B gelatin was modified with PEG-epoxide and nanoparticles were formed, under controlled temperature and pH, by solvent displacement using water-ethanol mixture. Further studies showed that these nanoparticles could efficiently encapsulate plasmid DNA and protected the payload, were internalized in cells by non-specific endocytosis and transported to peri-nuclear region within 12 hours, and resulted in high transgene expression efficiency in NIH-3T3 mouse fibroblast cells [6]. To determine the fate of intravenously (i.v.) administered radiolabeled PEGylated gelatin nanoparticles in solid tumor model, in the present study, we have investigated the long-circulating property in plasma and the biodistribution profile in Lewis lung carcinoma (LLC)-bearing female C57BL/6J mice.

## Experimental Methods

**Nanoparticle Preparation and Characterization:** PEG-modified gelatin was synthesized by reacting Type-B gelatin with PEG-epoxide as previously described [5]. Nanoparticles of the unmodified gelatin and PEGylated gelatin derivative were prepared by the ethanol precipitation method under controlled conditions of temperature and pH. Briefly, two-hundred mg of either gelatin or PEGylated gelatin derivative (with 30% of the available amine groups modified) was dissolved in 20 ml of deionized distilled water at 37°C until a clear solution was obtained. The pH of the resulting solution was adjusted to 7.00 with 0.2 M sodium hydroxide. Nanoparticles were formed by gradual displacement of the water with ethanol under controlled stirring conditions. In the final hydroalcoholic mixture of 100 ml, the ethanol to water volume ratio was maintained at 65:35. The formed gelatin or PEGylated gelatin nanoparticles were crosslinked with 1.0 ml of 40% (w/v) glyoxal at room temperature for 10 minutes. The amount of crosslinking agent was optimized based on prevention of the dissolution of the control and PEGylated gelatin nanoparticles in phosphate buffered saline (PBS, pH 7.4) at 37°C for at least 2 hours. Any unreacted aldehyde groups of glyoxal were quenched with aqueous 12% (w/v) sodium metabisulfite and the nanoparticle precipitate was centrifuged at 14,000 rpm for 90 minutes, washed twice with deionized distilled water, and were lyophilized. The nanoparticles were characterized by Coulter particle size analysis as previously described [5].

**<sup>125</sup>Iodine labeling of Nanoparticles:** Ten-mg of the control and PEGylated gelatin nanoparticles were suspended in a small volume (1.5 ml) of alkaline borate buffer (pH 8.5) sufficiently to hydrate the sample. We intentionally kept the aqueous buffer volume to a minimum to increase the efficiency of radioiodination of the nanoparticles. The suspension was then added to a pre-coated IODO-gen<sup>®</sup> tube and mixed by vortexing to insure that the nanoparticles had uniformly contacted the tube surface. Na-<sup>125</sup>I (2.5 mCi) was added to the nanoparticle suspension at 37°C and the system was mixed by vortexing. The radioiodination reaction proceeded for 30 minutes at room temperature with periodic mixing. At the completion of the reaction, 50 µl of tyrosine solution (10 mg/ml) was added as a scavenger of free <sup>125</sup>I. In addition, the nanoparticles were centrifuged at 5,000 rpm for 10 minutes and washed with a 65:35 ethanol-water mixture. Each wash was analyzed for radioactivity and the isotope was considered stably bound to the nanoparticles when the supernatant radioactivity had reached a minimum value. The remaining radioactivity on the nanoparticles was assumed to be tightly bound. The nanoparticles were dried under inert nitrogen gas stream overnight in the hood. The specific activity of the final gelatin and PEGylated gelatin nanoparticles was 0.40 µCi per mg and 0.28 µCi per mg respectively. The lower activity of PEGylated gelatin nanoparticles could be due to the presence of PEG chains. In addition, the stability of <sup>125</sup>I label bound to the nanoparticles at pH 7.4 was verified by incubating the radiolabeled nanoparticles in PBS at 37°C for up to 12 hours and periodically removing the supernatant for detection of free label.

**Biodistribution Studies in Lewis Lung Carcinoma Model:** Lewis lung carcinoma (LLC) cells, obtained from American Type Culture Collection (ATCC, Rockville, MD), were maintained through culture in Dubelco's modified Eagle's medium (DMEM) supplemented with glucose, L-glutamine, HEPES buffer, Pen-strep and fetal bovine serum at 37°C and 5% CO<sub>2</sub>.

The animal experiments described here were approved by the Northeastern University's Institutional Animal Care and Use Committee. Female C57BL/6J (5-6 weeks old, ~20 g), purchased from Charles River Laboratories (Wilmington, MA), were used as the animal model for the nanoparticle biodistribution studies. LLC model in C57BL/6J was selected based as our previous experience that allowed for reproducible induction of tumors in these animals. To initiate subcutaneous tumors, the left hind flank region of each mouse was shaved and disinfected. Approximately 30,000 LLC cells in Hank's balanced salt solution (HBSS) were injected in 100-200 µl subcutaneously in ether-anesthetized C57BL/6J mice. The animals were monitored daily following LLC cells inoculation until subcutaneous tumors were palpable and were approximately 10-15 mm in diameter in approximately one week following inoculation.

The tumor-bearing mice were divided for the administration of radiolabeled gelatin or PEGylated gelatin nanoparticles suspension in sterile water. After induction of light anesthesia by inhalation of isoflurane at a dose of 0.3 ml for approximately 15 seconds, the animal received an i.v. dose, via the tail vein, of 0.5 µCi of the gelatin and PEGylated gelatin nanoparticles in 100 µl using a 25 gauge, 1 inch butterfly needle fitted to a syringe. After 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, 10 hours and 12 hours post-administration of the gelatin and PEGylated gelatin nanoparticle formulations, the mice were sacrificed by CO<sub>2</sub> inhalation.


For each time point, a group of four animals were sacrificed and the radioactivity from the plasma, tumor mass, heart, lung, liver, kidney, spleen, and brain, as well as, the carcass was

determined using a Wallac 1470 Wizard™ automatic gamma counter (Wallac Inc., Gaithersburg, MD). The radioactivity, in disintegrations-per-minute (dpm), was converted into  $\mu\text{Ci}$  using a calibration standard. The total recovered radioactivity from the blood, tumor mass, all the organs, and the carcass was calculated. The total radioactivity recovered from all of the tissues, fluid, and carcass of the animals was accounted for based on the radioactivity in the injected dose of each nanoparticles.

## Results and Discussion


**Properties of Nanoparticles:** Gelatin and PEGylated gelatin nanoparticles of approximately 200 nm in diameter with spherical shape, as shown by scanning electron microscopy [5], were prepared for encapsulation and delivery of plasmid DNA to solid tumors. In addition, previous *in vitro* studies showed that both gelatin and PEGylated gelatin nanoparticles could encapsulate plasmid DNA (EGFP-N1, Clontech) at around 98% efficiency at 0.5% (w/w) loading levels. After about 12 hours, the PEGylated gelatin nanoparticles were predominantly found intact in the peri-nuclear region of the cells. Lastly, green fluorescence protein (GFP) expression in NIH-3T3 fibroblast cells by plasmid DNA-containing gelatin and PEGylated gelatin nanoparticles was observed under fluorescence confocal microscopy and by flow cytometry. GFP expression was evident after 12 hours of exposure of the DNA-containing nanoparticles and remained stable for up to 96 hours post-transfection. In addition, the percentage cells transfected by PEGylated gelatin nanoparticles increase significantly with time, probably due to the ability of the PEGylated gelatin nanoparticles to improve the intracellular stability of DNA in the presence of DNase and other endosomal/lysosomal or cytosolic degrading enzymes [6].

**Plasma Concentration Versus Time Profile:** The plasma concentration, expressed as percent recovered dose normalized to the weight of the fluid sample, versus time profile of the two formulations injected *in vivo* is shown in Figure 1. The main differences in the profiles of the fall in the radiolabel versus time for the two formulations lay in the significantly greater dose recovery in the plasma for the PEGylated gelatin nanoparticles over the control unmodified formulation. This increase in the dose recovered for the PEGylated formulation was seen for up to a total period of 3 hours, after which there was no differences in the plasma concentrations the two formulations. The greater recovery of the dose in the plasma with the PEG-modified nanoparticles as compared to the control was indicative of the long-circulating property of the PEGylated nanoparticles. The PEG-modified nanoparticles were probably capable of avoiding both complement activation and subsequent recognition and uptake by the components of RES. Surface PEGylation was found to prevent RES uptake for as long as 3 hours after which, the nanoparticles probably were taken up by the RES or underwent changes in biodistribution patterns as evident by their tumor and liver profiles. It is seen from the two profiles that at 0.5 hour time point, approximately 100% of the radiolabel was recovered from the plasma for the PEG-modified nanoparticles, compared to the 40% recovery for the unmodified nanoparticles. This is also indicative of immediate opsonization of the control unmodified nanoparticles on i.v. administration and immediate uptake by the RES system into organs such as the liver. After 3 hours, the PEGylated nanoparticles probably were digested by serum proteases and the steric repulsion effect by surface-bound PEG chains was not significant.



**Figure 1.** Percent recovered dose per gram in the plasma as a function of time for the radiolabeled [ $^{125}\text{I}$ -labeled] gelatin (■) and PEGylated gelatin (□) nanoparticles administered intravenously in Lewis lung carcinoma-bearing female C57BL/6J mice. Results are expressed as mean  $\pm$  S.D. (n = 4).

**Tumor Concentration Versus Time Profile:** Figure 2 shows the concentrations of  $^{125}\text{I}$ -labeled gelatin and PEGylated gelatin nanoparticles in the tumor mass, as expressed by percent recovered dose normalized to the weight the tumor, as a function of time. From this data, it is clear that the PEGylated nanoparticles were found to localize in the tumor at significantly higher concentrations than the gelatin nanoparticles for all of measured the time points. At the 3 hour time point, the differences between tumor concentrations of PEGylated gelatin and the control gelatin nanoparticles were insignificant. However, at other time points, approximately 4% of the recovered dose of PEGylated gelatin nanoparticles was present in the tumor mass for up to 12 hours post-administration. In contrast, only about 1% of the recovered dose of gelatin nanoparticles was found in the tumor for 12 hours. The ability of the PEGylated gelatin nanoparticles to target the tumor mass in significantly higher concentration can be explained on basis of the passive targeting ability of this formulation. The surface PEGylation of the PEG-modified gelatin formulation allows for longer-circulation time in the plasma when compared to the control gelatin nanoparticles. The long-circulating property allows PEGylated gelatin nanoparticles to preferentially distribute in the tumor mass and retention by the EPR effect of the vasculature.



**Figure 2.** Percent recovered dose per gram in the tumor as a function of time for the radiolabeled [ $^{125}\text{I}$ -labeled] gelatin (■) and PEGylated gelatin (□) nanoparticles administered intravenously in Lewis lung carcinoma-bearing female C57BL/6J mice. Results are expressed as mean  $\pm$  S.D. (n = 4).

**Pharmacokinetic Analysis of Plasma and Tumor Uptake:** Non-compartmental pharmacokinetic analysis of the plasma concentration versus time profiles was carried out and the parameters such as the elimination rate constant, half life, mean residence time, volume of distribution, total body clearance and area-under-the-curve for the two formulations in plasma are reported in Table 1. Notable in these results was the approximately 6-fold increase in the area-under-the-curve for the PEGylated formulation over the control gelatin formulation. This along with the relatively smaller elimination rate constant corresponds to greater bioavailability of the PEG-modified formulation over the control formulation. This coupled with the observation that the PEGylated formulation has a greater half-life in the plasma (25.1 h for the PEGylated gelatin nanoparticles as compared to 17.1 h for gelatin nanoparticles), is a confirmation of the stealth nature of the formulation that allows it to circulate for longer time in the plasma, by avoiding RES uptake.

**Table 1:** Non-Compartmental Pharmacokinetic Parameters from Plasma for Gelatin and Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles in Lewis Lung Carcinoma-Bearing Mice

| Pharmacokinetic Parameter                   | Gelatin Nanoparticles | PEGylated Gelatin Nanoparticles |
|---|-----------------------|---------------------------------|
| Elimination Rate Constant ( $h^{-1}$ )      | $0.041 \pm 0.006^*$   | $0.028 \pm 0.003$               |
| Half-Life (h)                               | $17.1 \pm 1.47$       | $25.1 \pm 2.24$                 |
| Mean Residence Time (h)                     | $29.7 \pm 2.14$       | $36.2 \pm 6.56$                 |
| Volume of Distribution (g)                  | $2.44 \pm 0.12$       | $0.55 \pm 0.01$                 |
| Total Body Clearance (g/h)                  | $0.099 \pm 0.004$     | $0.015 \pm 0.006$               |
| Area-Under-the-Curve ( $\mu Ci \cdot h/g$ ) | $4.05 \pm 0.24$       | $26.2 \pm 3.27$                 |

\* Mean  $\pm$  S.D. (n = 4)

Non-compartmental pharmacokinetic analysis of the tumor concentrations as a function of time results are shown in Table 2. There was an approximate 6.3-fold increase (120 h as compared to the 18.8 h) in the tumor-half life of the PEGylated gelatin nanoparticles over the control formulation and a 5-fold increase in the area-under-the-curve. These results are again indicative of the enhanced retention of the PEGylated gelatin nanoparticles in the tumor compared to the control. This can be explained on the basis of the EPR effect coupled with the protective steric effect of the PEG chains on the surface that allowed these surface modified nanoparticles to be not only retained better in the tumor because of an increase in the hydrodynamic diameter of the particle that precludes its exit through tumor vasculature but also protects it in the degradative tumor environment.

**Table 2:** Non-Compartmental Pharmacokinetic Parameters from Tumor for Gelatin and Poly(Ethylene Glycol)-Modified Gelatin Nanoparticles in Lewis Lung Carcinoma-Bearing Mice

| Pharmacokinetic Parameter                   | Gelatin Nanoparticles | PEGylated Gelatin Nanoparticles |
|---|-----------------------|---------------------------------|
| Elimination Rate Constant ( $h^{-1}$ )      | $0.037 \pm 0.001^*$   | $0.006 \pm 0.001$               |
| Half-Life (h)                               | $18.8 \pm 3.60$       | $120.5 \pm 11.7$                |
| Mean Residence Time (h)                     | $27.2 \pm 4.13$       | $173.9 \pm 14.9$                |
| Volume of Distribution (g)                  | $10.7 \pm 2.24$       | $13.4 \pm 0.28$                 |
| Total Body Clearance (g/h)                  | $0.39 \pm 0.12$       | $0.077 \pm 0.003$               |
| Area-Under-the-Curve ( $\mu Ci \cdot h/g$ ) | $1.02 \pm 0.02$       | $5.19 \pm 1.10$                 |

\* Mean  $\pm$  S.D. (n = 4)

## Conclusions

We have examined the biodistribution profiles following intravenous administration of gelatin and PEGylated gelatin nanoparticles to subcutaneous Lewis lung carcinoma-bearing C57BL/6J mice. The results show that PEGylated gelatin nanoparticles remained in the blood pool for a longer period of time as compared to the gelatin nanoparticles. In addition higher tumor accumulation of PEGylated gelatin nanoparticles was observed, which remained constant for up to 12 hours post-administration. Unmodified gelatin nanoparticles were rapidly removed from the circulation by the RES mechanism that resulted in higher concentrations in the liver and spleen within a few hours of administration. Overall, these results show that PEGylated gelatin nanoparticles were able to remain the circulation and could be effective in passive targeting hydrophilic macromolecules, such as proteins and DNA, to solid tumors.

## Acknowledgements

This study was supported by a grant (RO1-CA095522) from the National Cancer Institute of the National Institutes of Health.

## References

1. Jain, R.K., *Adv Drug Deliv Rev*, **46**: 149-68 (2001).
2. Maeda, H., *et al.*, *J. Cancer Research*, **85**: 331-334 (1994).
3. Yuan, F., *Sem. in Rad. Oncol.*, **8**: 164-175 (1998).
4. Moghimi, S.M., *et al.*, *Pharmacol Rev*, **53**: 283-318 (2001).
5. Kaul, G. and M. Amiji, *Pharm Res*, **19**: 1061-1067 (2002).
6. Kaul, G. and M. Amiji, *J. Pharm. Sci.*, 2004 (In press).